Abstract
Prostate
cancer (PCA), the most common cancer in men, accounted
for 1.3 million new incidences in 2018. An increase in incidences
is an issue of concern that should be addressed. Of all the reported
prostate cancers, 85% were detected in stages III and IV, making them
difficult to treat. Conventional drugs gradually lose their efficacy
due to the developed resistance against them, thus requiring newer
therapeutic agents to be used as monotherapy or combination. Recent
research regarding treatment options has attained remarkable speed
and development. Therefore, in this context, drug repurposing comes
into the picture, which is defined as the “investigation of
the off-patent, approved and marketed drugs for a novel therapeutic
indication” which saves at least 30% of the time and cost,
reducing the cost of treatment for patients, which usually runs high
in cancer patients. The anticancer property of cardiac glycosides
in cancers was tested in the early 1980s. The trend then shifts toward
treating prostate cancer by repurposing other cardiovascular drugs.
The current review mainly emphasizes the advantageous antiprostate
cancer profile of conventional CVS drugs like cardiac glycosides,
RAAS inhibitors, statins, heparin, and beta-blockers with underlying
mechanisms.